12:14pm Friday 15 December 2017

NYU Study Identifies Method for Detecting Latent Stage of Lymphedema

Many are aware that hair loss is a common side effect associated with chemotherapy. However, another albeit common late side effect of cancer treatment is the abnormal swelling of one or more limbs, known as lymphedema. Lymphedema is most commonly the result of an obstruction or disruption of the lymphatic system that occurs immediately after cancer treatment or 1-5, even 20 years after.

However, unlike hair loss, which can occur two to four weeks after beginning treatment, lymphedema symptoms may not be as quick to manifest. A latent period may exist months or even years before overt swelling occurs. During this latency, changes in the affect limb cannot be detected objective measures, other than the persistence of other symptoms. Given the late presentation of visible symptoms, self reporting plays an important role in early detection.

A new study led by researchers at the New York University College of Nursing (NYUCN) examines the validity, sensitivity, and specificity of symptoms for detecting breast cancer-related related lymphedema. The study, “Symptom report in detecting breast cancer-related lymphedema,” published in Breast Cancer: Targets and Therapy, also determines the best clinical cutoff point for the count of symptoms that maximized the sum of sensitivity and specificity.

The NYU researchers collected data from a total of 250 women categorized into three cohorts. Sixty participants were healthy female adults, forty-two were breast cancer survivors who had been previously diagnosed with lymphedema, and 148 were at-risk breast cancer survivors.

Healthy participants were significantly younger than the breast cancer survivors with lymphedema and at-risk survivors. Also notable, there were considerably more nonwhite survivors with lymphedema.

“In part one of our review we evaluated twenty-two symptoms associated with breast cancer-related lymphedema, and in part two we assessed different dimensions of symptom distress,” said the study’s first author, Mei R. Fu, PhD, RN, ACNS-BC, FAAN, associate professor of Chronic Disease Management at NYUCN.

Women who reported arm heaviness, arm firmness, increased arm temperature, tightness, limited arm movement, tin­gling, and arm aching had more than five times the odds of lymphedema compared to women without these symptoms, while women who reported limited finger movement, limited elbow movement, and limited wrist movement had more than four times the odds of lymphedema compared to women without these symptoms. Women who reported pain in the affected arm also had nearly twice the odds of lymphedema in comparison to those who reported no pain in the affected arm.

“While each of these symptoms and its dimensions is diagnostically relevant, we found that we could differentiate healthy adults from breast cancer survivors with lymphedema and those at risk for lymphedema by a count of their symptoms,” said Dr. Fu.

A diagnostic cutoff of three symptoms discriminated breast cancer survivors with lymphedema from healthy women with a sensitivity of 94% and a specificity of 97%, while a diagnostic cutoff of nine symptoms discriminated at-risk survivors from survivors with lymphedema with a sensitivity of 64% and a specificity of 80%.

Dr. Fu and the team researchers are hopeful that in the absence of objective measurements capable of detect­ing latent stage of lymphedema, that the count of symptoms could be an extremely cost-effective initial screening tool for lymphedema, and encourage its use in clinical practice.

Researcher Affiliations: Mei R Fu1, Deborah Axelrod2,3, Charles M Cleland1, Zeyuan Qiu4, Amber A Guth2,3, Robin Kleinman2, Joan Scagliola2, and Judith Haber1.

1. College of Nursing, New York University

2. Department of Surgery, NYU School of Medicine

3. NYU Clinical Cancer Center, New York, NY

4. Department of Chemistry and Environmental Science, New Jersey Institute of Technology, Newark, NJ, USA

Acknowledgements: This study was supported by the Avon Foundation, National Institutes of Health (NIMHD Project P60 MD000538-03), judges and lawyers for breast cancer alert, and the vital fund. The contents of this study are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The funders had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

About New York University College of Nursing

NYU College of Nursing is a global leader in nursing education, research, and practice. It offers a Bachelor of Science in Nursing, a Master of Science and Post-Master’s Certificate Programs, a Doctor of Philosophy in Research Theory and Development, and a Doctor of Nursing Practice degree.  For more information, visit https://nursing.nyu.edu/

About NYU Langone Medical Center

NYU Langone Medical Center, a world-class, patient-centered, integrated academic medical center, is one of the nation’s premier centers for excellence in clinical care, biomedical research, and medical education. Located in the heart of Manhattan, NYU Langone is composed of four hospitals—Tisch Hospital, its flagship acute care facility; Rusk Rehabilitation; the Hospital for Joint Diseases, the Medical Center’s dedicated inpatient orthopaedic hospital; and Hassenfeld Children’s Hospital, a comprehensive pediatric hospital supporting a full array of children’s health services across the Medical Center—plus the NYU School of Medicine, which since 1841 has trained thousands of physicians and scientists who have helped to shape the course of medical history. The Medical Center’s tri-fold mission to serve, teach, and discover is achieved 365 days a year through the seamless integration of a culture devoted to excellence in patient care, education, and research. For more information, go to www.NYULMC.org

Press Contact: Christopher James | (212) 998-6876


Share on:
or:

MORE FROM Cancers

Health news